FAM
FBLG icon

Flaharty Asset Management’s FibroBiologics FBLG Stock Holding History

Flaharty Asset Management’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-735
Closed -$3.31K – 143
2025
Q4 		$3.31K Hold
735
– – ﹤0.01% 141
2025
Q3 		$8.03K Hold
735
– – ﹤0.01% 130
2025
Q2 		$9.15K Hold
735
– – ﹤0.01% 129
2025
Q1 		$13.2K Hold
735
– – ﹤0.01% 303
2024
Q4 		$29.4K Hold
735
– – ﹤0.01% 128
2024
Q3 		$45.4K Buy
+735
New +$48.9K 0.01% 220

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Flaharty Asset Management's FBLG Position: Q1 2026 in Review

Flaharty Asset Management sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 735 shares — an estimated $3.31K sold.

Flaharty Asset Management first reported a position in FBLG in Q3 2024 and held it in 6 quarters. The position peaked at $45.4K in Q3 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Flaharty Asset Management reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Flaharty Asset Management sold 735 FibroBiologics shares in Q1 2026, an estimated $3.31K.
  • Flaharty Asset Management first reported a position in FibroBiologics in Q3 2024 and held it in 6 quarters.
  • Flaharty Asset Management's FibroBiologics position peaked at $45.4K in Q3 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Flaharty Asset Management's 13F filing for Q1 2026, filed 5 May 2026.